Targeting natural killer cells and natural killer T cells in cancer
By É. Vivier, S. Ugolini, D. Blaise, Christian Chabannon, L. Brossay. Nature reviews. Immunology, 2012
829 citations recorded by the source corpus.
Natural killer (NK) cells and natural killer T (NKT) cells are subsets of lymphocytes that share some phenotypical and functional similarities. Both cell types can rapidly respond to the presence of tumour cells and participate in antitumour immune responses. This has prompted interest in the development of innovative cancer therapies that are based on the manipulation of NK and NKT cells. Recent studies have highlighted how the immune reactivity of NK and NKT cells is shaped by the environment in which they develop. The rational use of these cells in cancer immunotherapies awaits a better understanding of their effector functions, migratory patterns and survival properties in humans.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/dcf553aaa0061a7361bba9cbee7907ce610a231b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
Citations in the corpus
- Natural killer cells in cancer biology and therapy (2020, background): “Although sharing many similarities, compared with effector T cells, NK cells are more cytotoxic to tumors and possess lower immunogenicity [10].”
- Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution. (2016, neutral): “…of the innate immune defense, recognizing transformed cells independently of antibodies or major histocompatibility complex (MHC) restriction (Vivier et al., 2012; Brodin et al., 2012), while T cells are cyto- 4 Cell Metabolism 23, 1–9, March 8, 2016 ª2016 Elsevier Inc. toxic effector cells…”
- Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells (2018, background): “…on enhancing T cell responses, but there has been a recent surge of interest in harnessing the relatively underexplored NK cell compartment for therapeutic interventions (Cerwenka and Lanier, 2018; Guillerey and Smyth, 2016; Rautela et al., 2018; Vivier et al., 2012; Chiossone et al., 2018).”